Vinorelbine-associated myelopathy in a patient who previously received paclitaxel: a case report.
Vinorelbine seems to cause less neurotoxicity than other vinca alkaloids because of its selective activity on mitotic cells over axonal microtubules. Clinical trials report very mild peripheral neurotoxicity with distal paresthesiae and there are no reports of myelopathy in these series of patients. The authors describe a patient who developed a rare event of myelopathy while on vinorelbine for non-small-cell lung cancer.
Han
J Y
JY
Departments of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul. jymama@cmc.cuk.ac.kr
Choi
B G
BG
Song
D H
DH
Ahn
J G
JG
Yoon
J S
JS
Lee
K S
KS
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D013116:Spinal Cord / Q000473:pathology; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000473:pathology; D014747:Vinblastine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine